In two phase 3b trials (MUSETTE, 860 relapsing MS; GAVOTTE, 753 primary progressive MS), bodyweight-adjusted high-dose ocrelizumab did not reduce 12-week confirmed disability progression vs 600 mg (34% vs 37%, HR 0·93; 47% vs 49%, HR 0·95); safety was similar.
RCTn = 1,613
Hauser et al. Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials